Moderna (MRNA) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Moderna, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track MRNA live on Mooboard →

31–90 days2

  • Sep 22, 2026
    Moderna(MRNA)Phase 2/3 readout
    mRNA-1403 · Phase 1 / Phase 2 · Norovirus Acute Gastroenteritis
    NCT05992935: Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age. Primary completion 2026-09-22 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 5, 2026
    Moderna(MRNA)Phase 2/3 readout
    mRNA-1189 · Phase 1 / Phase 2 · Epstein-Barr Virus Infection
    NCT05164094: A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults. Primary completion 2026-10-05 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

Later11

  • Nov 30, 2026
    Moderna(MRNA)Phase 2/3 readout
    mRNA-3745 · Phase 1 / Phase 2 · Glycogen Storage Disease
    NCT05095727: A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a). Primary completion 2026-11-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 28, 2027
    Moderna(MRNA)Phase 2/3 readout
    mRNA-1018-H5 · Phase 3 · Influenza
    NCT07496450: A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults. Primary completion 2027-01-28 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 15, 2027
    Moderna(MRNA)Phase 2/3 readout
    mRNA-1403 · Phase 3 · Acute Gastroenteritis; Norovirus Acute Gastroenteritis
    NCT06592794: A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis. Primary completion 2027-02-15 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Aug 31, 2027
    Moderna(MRNA)Phase 2/3 readout
    mRNA-3927 · Phase 1 / Phase 2 · Propionic Acidemia
    NCT04159103: Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia. Primary completion 2027-08-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 9, 2028
    Moderna(MRNA)Phase 2/3 readout
    mRNA-1982 · Phase 2 · Lyme Disease
    NCT07561294: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age). Primary completion 2028-11-09 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 8, 2029
    Moderna(MRNA)Phase 2/3 readout
    mRNA-1195 · Phase 2 · Multiple Sclerosis
    NCT06735248: A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years. Primary completion 2029-01-08 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 4, 2029
    Moderna(MRNA)Phase 2/3 readout
    mRNA-3927 · Phase 1 / Phase 2 · Propionic Acidemia
    NCT05130437: A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study. Primary completion 2029-12-04 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 17, 2030
    Moderna(MRNA)Phase 2/3 readout
    mRNA-2808 · Phase 1 / Phase 2 · Relapsed or Refractory Multiple Myeloma
    NCT07116616: A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma. Primary completion 2030-06-17 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 18, 2032
    Moderna(MRNA)Phase 2/3 readout
    mRNA-4359 · Phase 1 / Phase 2 · Advanced Solid Tumors
    NCT05533697: Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors. Primary completion 2032-02-18 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 30, 2032
    Moderna(MRNA)Phase 2/3 readout
    mRNA-4157 · Phase 2 · Melanoma
    NCT03897881: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942). Primary completion 2032-11-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 2, 2034
    Moderna(MRNA)Phase 2/3 readout
    mRNA-3705 · Phase 1 / Phase 2 · Methylmalonic Acidemia
    NCT05295433: An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705. Primary completion 2034-04-02 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗

How Moderna has moved — past-year price reactions

How binary is MRNA? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

2.5%
typical day (1Y)
10
±10% days
69.5%
annualized vol
250
trading days
Largest single-day moves
  • +17%2026-01-13no matched headline
  • +16%2026-03-04no matched headline
  • +15.8%2026-01-21no matched headline
  • +13.9%2025-10-30no matched headline
  • +12.6%2026-06-26no matched headline
  • +12%2026-05-08no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Moderna — active clinical pipeline

Moderna's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

19 assets23 programsPh1 7Ph2 11Ph3 3· 2 post-marketing (Ph4)
AreasOncologyNeuroscienceInfectiousOther
mRNA-1345Infectious
Phase 1
Respiratory Syncytial Virus
Phase 3
Respiratory Syncytial Virus
mRNA-1403Other
Phase 2
Norovirus Acute Gastroenteritis
Phase 3
Acute Gastroenteritis
mRNA-1018-H5Infectious
Phase 3
Influenza
mRNA-1189Infectious
Phase 1
Epstein-Barr Virus
Phase 2
Epstein-Barr Virus Infection
mRNA-4157Oncology
Phase 1
Solid Tumors
Phase 2
Melanoma
mRNA-1195Neuroscience
Phase 2
Multiple Sclerosis
mRNA-1647Infectious
Phase 2
Cytomegalovirus Infection
mRNA-1982Other
Phase 2
Lyme Disease
mRNA-2808Oncology
Phase 2
Relapsed or Refractory Multiple Myeloma
mRNA-3705Other
Phase 2
Methylmalonic Acidemia
mRNA-3745Other
Phase 2
Glycogen Storage Disease
mRNA-3927Other
Phase 2
Propionic Acidemia (2)
mRNA-4359Oncology
Phase 2
Advanced Solid Tumors
mRNA-0184Other
Phase 1
Healthy volunteers
mRNA-1195.1Infectious
Phase 1
Epstein-Barr Virus Infection
mRNA-1469Infectious
Phase 1
Ebola-Bundibugyo Virus Disease (Ebola-BDBV)
mRNA-4106Oncology
Phase 1
Advanced Solid Tumors

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

See the full biopharma catalyst calendar across all covered companies.